clinical trial · NCT07705737
Rademikibart IV for Acute Asthma and COPD Exacerbation
Connect Biopharm LLC·phase2·not yet recruiting·n = 40
Asthma AcuteCOPD Exacerbation AcuteRademikibart
brief summary
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
started
Jul 30, 2026
primary completion
Dec 1, 2026
completion
Jan 1, 2027
last updated
Jul 15, 2026
detailed description
A phase 2, open-label, single-arm trial to assess the efficacy of a single 300 mg dose of rademikibart administered as a 2-minute IV infusion (IV push) on lung function in participants with asthma or COPD with type 2 inflammation who require an urgent healthcare visit for the treatment of acute exacerbation.
official title
A Phase 2, Open-Label, Single-Arm Trial to Evaluate IV Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Asthma and or COPD With Type 2 Inflammation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol